ONVO (Organovo Corp) Earnings growth in current year

ONVO (Organovo Corp) - company brandmark

The prospects for validating 3D platforms for metabolic drug testing are shaping a long-term trend, while the lack of revenue is already priced in. The year-over-year shift in EPS figures demonstrates profitability dynamics, where the 0.00 level reflects the current magnitude for Organovo Holdings, Inc. (ONVO). However, slow commercialization and the risk of failure in liver bioprinting create challenges, which are further exacerbated by geopolitical fragmentation and sanction-based equipment export restrictions.

ONVO: Organovo Holdings, Inc. Earnings per share growth in current year 07/04/2022 - 04/24/2025

Financial and market metric breakdowns for Organovo Holdings (ONVO)

- share price and expert price forecast:
- business market valuation indicators:
Basic company analysis:ONVO - Organovo Corp
Finished products of Organovo

This indicator reflects the year-over-year earnings per share (EPS) dynamics, allowing for an assessment of capital efficiency growth rates. By analyzing annual EPS fluctuations, an investor determines the company's life cycle stage and its competitiveness within the sector. For Organovo Holdings, Inc. (ONVO), which invests in 3D bioprinting and highly skilled scientists, this metric demonstrates the impact of R&D costs and grants on final profitability.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|Aardvark Therapeutics Inc (AARD) - Earnings per share growth in current year|Net earnings per share change in current year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth in current year|Net earnings per share growth this year Biomea Fusion (BMEA)|Earnings growth in current year QNCX|Net earnings per one share growth for the current year GUTS|Earnings growth in current year VTVT (vTv Therapeutics Inc.)|Earnings per share increase in current year ATPC|Pluristem Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year synlogictx.com SYBX|LPCN: Earnings growth in current year|Matinas BioPharma Holdings, Inc. - Earnings per share increase in current year|SPRB (Spruce Biosciences Inc.) - Earnings growth in current year|galecto.com (GLTO) - Expected net earnings per share growth this year|Earnings per share growth in current year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year